Akebia GAAP EPS of -0.04, revenue of 43.67M
AKBA Stock | USD 1.92 0.06 3.03% |
About 66% of Akebia Ther's investor base is looking to short. The analysis of the overall investor sentiment regarding Akebia Ther suggests that many traders are alarmed. The current market sentiment, together with Akebia Ther's historical and current headlines, can help investors time the market. In addition, many technical investors use Akebia Ther stock news signals to limit their universe of possible portfolio assets.
Akebia |
Akebia Therapeutics reports Q2 2024 financial results with GAAP EPS of -0.04 and revenue of 43.67M, down 22.5 percent year-over-year.
Read at seekingalpha.com
Akebia Ther Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Akebia Ther can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Akebia Ther Fundamental Analysis
We analyze Akebia Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akebia Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akebia Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Akebia Ther is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Akebia Ther Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Akebia Ther stock to make a market-neutral strategy. Peer analysis of Akebia Ther could also be used in its relative valuation, which is a method of valuing Akebia Ther by comparing valuation metrics with similar companies.
Peers
Akebia Ther Related Equities
ELEV | Elevation Oncology | 15.38 | ||||
XFOR | X4 Pharmaceuticals | 13.43 | ||||
ENVB | Enveric Biosciences | 9.09 | ||||
OCEA | Ocean Biomedical | 1.47 | ||||
CDTX | Cidara Therapeutics | 1.58 | ||||
PLX | Protalix Biotherapeutics | 1.64 | ||||
MCRB | Seres Therapeutics | 3.23 | ||||
HEPA | Hepion Pharmaceuticals | 6.35 |
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Bonds Directory Find actively traded corporate debentures issued by US companies |